2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2280

Evidence Based Recommendations for the Management of Cryopyrin Associated Periodic Syndromes (CAPS)
Abstract Number: 444

Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis
Abstract Number: 28

Evidence for Receptor Activator of NF-Kb (RANK)-Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis
Abstract Number: 1263

Evidence for the Involvement of NK Cells in Antisynthetase Syndrome
Abstract Number: 668

Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Abstract Number: 1455

Ex Vivo-Expanded, but Not in Vitro-Induced, Human Regulatory T Cells Are Suitable for Cell Therapy in Rheumatological Autoimmune Diseases Thanks to Stable FOXP3 Demethylation
Abstract Number: 1882

Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice
Abstract Number: 1934

Examing Why Minority Women Are Risk Averse : A Qualitative Study
Abstract Number: 843

Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis
Abstract Number: 2897

Exercise Therapy and/or Manual Therapy for Hip or Knee Osteoarthritis: 2-Year Follow-up of a Randomized Controlled Trial
Abstract Number: 889

Exercise, Manual Therapy, and Use of Booster Sessions in Physical Therapy for Knee OA: A Multi-Center Randomized Clinical Trial
Abstract Number: 2838

Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus
Abstract Number: 2238

Exploratory Six Month Phase IIa Study of a Potential Disease Modifying Drug in Patients with OA of the Knee
Abstract Number: 997

Explore Translational Pharmacokinetics/Pharmacodynamics Response/Efficacy Relationship of a Novel Bruton’s Tyrosine Kinase Inhibitor in Rat Collagen-Induced Arthritis Model
Abstract Number: 1591

Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].